$1.02
OKYO Pharma Ltd ADR is a biotechnology business based in the US. OKYO Pharma Ltd ADR shares (OKYO) are listed on the NASDAQ and all prices are listed in US Dollars. OKYO Pharma Ltd ADR employs 7 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy OKYO Pharma Ltd ADR stock
How to buy OKYO Pharma Ltd ADR stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – OKYO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy OKYO Pharma Ltd ADR stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
OKYO Pharma Ltd ADR stock price (NASDAQ: OKYO)
Use our graph to track the performance of OKYO stocks over time.OKYO Pharma Ltd ADR shares at a glance
Latest market close | $1.02 |
---|---|
52-week range | $1.81 - $6.11 |
50-day moving average | $2.29 |
200-day moving average | $2.32 |
Wall St. target price | N/A |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.01 |
Is it a good time to buy OKYO Pharma Ltd ADR stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
OKYO Pharma Ltd ADR price performance over time
Historical closes compared with the close of $1.02 from 2024-09-06
1 week (2024-08-30) | -15.00% |
---|---|
1 month (2024-08-07) | 2.00% |
3 months (2024-06-07) | -19.69% |
6 months (2024-03-07) | -27.66% |
1 year (2023-09-07) | -47.42% |
---|---|
2 years (2022-09-07) | -67.20% |
3 years (2021-09-03) | N/A |
5 years (2019-09-03) | N/A |
OKYO Pharma Ltd ADR financials
Gross profit TTM | $-3,599,629 |
---|---|
Return on assets TTM | -67.65% |
Return on equity TTM | -130.43% |
Profit margin | 0% |
Book value | $0.13 |
Market Capitalization | $46.5 million |
TTM: trailing 12 months
OKYO Pharma Ltd ADR share dividends
We're not expecting OKYO Pharma Ltd ADR to pay a dividend over the next 12 months.
OKYO Pharma Ltd ADR share price volatility
Over the last 12 months, OKYO Pharma Ltd ADR's shares have ranged in value from as little as $1.81 up to $6.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OKYO Pharma Ltd ADR's is -0.1069. This would suggest that OKYO Pharma Ltd ADR's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, OKYO Pharma Ltd ADR has bucked the trend.
OKYO Pharma Ltd ADR overview
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. .
Frequently asked questions
What percentage of OKYO Pharma Ltd ADR is owned by insiders or institutions?Currently 0.057% of OKYO Pharma Ltd ADR shares are held by insiders and 0.005% by institutions. How many people work for OKYO Pharma Ltd ADR?
Latest data suggests 7 work at OKYO Pharma Ltd ADR. When does the fiscal year end for OKYO Pharma Ltd ADR?
OKYO Pharma Ltd ADR's fiscal year ends in March. Where is OKYO Pharma Ltd ADR based?
OKYO Pharma Ltd ADR's address is: 55 Park Lane, London, United Kingdom, W1K 1NA What is OKYO Pharma Ltd ADR's ISIN number?
OKYO Pharma Ltd ADR's international securities identification number is: US6793451088
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question